Compare AAON & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | ERAS |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 1995 | 2021 |
| Metric | AAON | ERAS |
|---|---|---|
| Price | $75.52 | $14.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $134.75 | $24.11 |
| AVG Volume (30 Days) | 1.0M | ★ 4.9M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,442,076,000.00 | N/A |
| Revenue This Year | $60.43 | N/A |
| Revenue Next Year | $18.59 | N/A |
| P/E Ratio | $64.48 | ★ N/A |
| Revenue Growth | ★ 20.11 | N/A |
| 52 Week Low | $71.91 | $2.11 |
| 52 Week High | $150.46 | $24.28 |
| Indicator | AAON | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 46.18 |
| Support Level | N/A | $13.56 |
| Resistance Level | $89.67 | $15.03 |
| Average True Range (ATR) | 3.68 | 1.02 |
| MACD | -1.22 | 0.04 |
| Stochastic Oscillator | 18.59 | 45.32 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which derives maximum revenue, engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.